Medline ® Abstract for Reference 25
of 'Pharmacotherapy for generalized anxiety disorder in adults'
25
TI
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
AU
Allgulander C, Hackett D, Salinas E
SO
Br J Psychiatry. 2001;179:15.
BACKGROUND:
Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.
AIMS:
To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.
METHOD:
A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.
RESULTS:
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.
CONCLUSIONS:
Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
AD
Neurotec/Psychiatry, Huddinge University Hospital, Huddinge, Sweden.
PMID